المؤلفون: I. Pokataev A., M. Lyadova A., M. Fedyanin Yu., A. Tryakin A., V. Chubenko F., F. Moiseenko V., L. Zagorskaya A., M. Stepanova L., A. Androsova V., D. Nosov A., N. Karpova V., O. Kit I., L. Vladimirova Yu., I. Popova L., A. Belonogov V., D. Ponomarenko M., D. Yukalchuk Yu., V. Shikina E., N. Ivanova V., A. Khasanova I., A. Kruglov D., I. Stradaeva Yu., A. Perepletova S., V. Filippova M., N. Buzova L., O. Khavaneva V., Kh. Musaeva S., A. Goryainova Yu., O. Romanchuk V., I. Tespizhek Sh., S. Tyulyandin A., И. Покатаев А., М. Лядова А., М. Федянин Ю., А. Трякин А., В. Чубенко А., Ф. Моисеенко В., Л. Загорская А., М. Степанова Л., А. Андросова В., Д. Носов А., Н. Карпова В., О. Кит И., Л. Владимирова Ю., И. Попова Л., А. Белоногов В., Д. Пономаренко М., Д. Юкальчук Ю., В. Шикина Е., Н. Иванова В., А. Хасанова И., А. Круглов Д., И. Страдаева Ю., А. Переплетова С., В. Филиппова М., Н. Бузова Л., О. Хаванева В., Х. Мусаева С., А. Горяинова Ю., О. Романчук В., И. Теспижек Ш., С. Тюляндин А.

المصدر: Meditsinskiy sovet = Medical Council; № 19 (2019); 74-82 ; Медицинский Совет; № 19 (2019); 74-82 ; 2658-5790 ; 2079-701X ; 10.21518/2079-701X-2019-19

مصطلحات موضوعية: pancreatic cancer, gemcitabine, nab-paclitaxel, chemotherapy, рак поджелудочной железы, гемцитабин, nab-паклитаксел, химиотерапия

وصف الملف: application/pdf

Relation: https://www.med-sovet.pro/jour/article/view/5190/4717; Burris H.A., Moore M.J., Andersen J., Green M.R., Rothenberg M.L., Modiano M.R., Cripps M.C., Portenoy R.K., Storniolo A.M., Tarassoff P. et al. Improvements in Survival and Clinical Benefit with Gemcitabine as First-Line Therapy for Patients with Advanced Pancreas Cancer: A Randomized Trial. JCO. 1997;15(6):2403–2413. doi:10.1200/JCO.1997.15.6.2403.; Berlin J.D., Catalano P., Thomas J.P., Kugler J.W., Haller D.G., Benson A.B. Phase III Study of Gemcitabine in Combination With Fluorouracil Versus Gemcitabine Alone in Patients With Advanced Pancreatic Carcinoma: Eastern Cooperative Oncology Group Trial E2297. JCO. 2002;20(15):3270–3275. doi:10.1200/JCO.2002.11.149.; Rocha Lima C.M., Green M.R., Rotche R., Miller W.H., Jeffrey G.M., Cisar L.A., Morganti A., Orlando N., Gruia G., Miller L.L. Irinotecan Plus Gemcitabine Results in No Survival Advantage Compared With Gemcitabine Monotherapy in Patients With Locally Advanced or Metastatic Pancreatic Cancer Despite Increased Tumor Response Rate. JCO. 2004;22(18):3776–3783. doi:10.1200/JCO.2004.12.082.; Oettle H., Richards D., Ramanathan R.K., van Laethem J.L., Peeters M., Fuchs M., Zimmermann A., John W., Von Hoff D., Arning M. et al. A Phase III Trial of Pemetrexed plus Gemcitabine versus Gemcitabine in Patients with Unresectable or Metastatic Pancreatic Cancer. Annals of Oncology. 2005;16(10):1639–1645. doi:10.1093/annonc/mdi309.; Louvet C., Labianca R., Hammel P., Lledo G., Zampino M.G., André T., Zaniboni A., Ducreux M., Aitini E., Taïeb J. et al. Gemcitabine in Combination With Oxaliplatin Compared With Gemcitabine Alone in Locally Advanced or Metastatic Pancreatic Cancer: Results of a GERCOR and GISCAD Phase III Trial. JCO. 2005;23(15):3509–3516. doi:10.1200/JCO.2005.06.023.; Heinemann V., Quietzsch D., Gieseler F., Gonnermann M., Schönekäs H., Rost A., Neuhaus H., Haag C., Clemens M., Heinrich B. et al. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Gemcitabine Alone in Advanced Pancreatic Cancer. JCO. 2006;24(24):3946–3952. doi:10.1200/JCO.2005.05.1490.; Herrmann R., Bodoky G., Ruhstaller T., Glimelius B., Bajetta E., Schüller J., Saletti P., Bauer J., Figer A., Pestalozzi B. et al. Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. JCO. 2007;25(16):2212–2217. doi:10.1200/JCO.2006.09.0886.; Poplin E., Feng Y., Berlin J., Rothenberg M.L., Hochster H., Mitchell E., Alberts S., O’Dwyer P., Haller D., Catalano P. et al. Phase III, Randomized Study of Gemcitabine and Oxaliplatin Versus Gemcitabine (Fixed-Dose Rate Infusion) Compared With Gemcitabine (30-Minute Infusion) in Patients With Pancreatic Carcinoma E6201: A Trial of the Eastern Cooperative Oncology Group. JCO. 2009;27(23):3778–3785. doi:10.1200/JCO.2008.20.9007.; Cunningham D., Chau I., Stocken D.D., Valle J.W., Smith D., Steward W., Harper P.G., Dunn J., TudurSmith C., West J. et al. Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine Plus Capecitabine in Patients With Advanced Pancreatic Cancer. JCO. 2009;27(33):5513–5518. doi:10.1200/JCO.2009.24.2446.; Colucci G., Labianca R., Di Costanzo F., Gebbia V., Cartenì G., Massidda B., Dapretto E., Manzione L., Piazza E., Sannicolò M. et al. Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared With Single-Agent Gemcitabine As First-Line Treatment of Patients With Advanced Pancreatic Cancer: The GIP-1 Study. JCO. 2010;28(10):1645–1651. doi:10.1200/JCO.2009.25.4433.; Von Hoff D.D., Ervin T., Arena F.P., Chiorean E.G., Infante J., Moore M., Seay T., Tjulandin S.A., Ma W.W., Saleh M.N. et al. Increased Survival in Pancreatic Cancer with Nab-Paclitaxel plus Gemcitabine. N Engl J Med. 2013;369(18):1691–1703. doi:10.1056/NEJMoa1304369.; Tabernero J., Chiorean E.G., Infante J.R., Hingorani S.R., Ganju, V., Weekes C., Scheithauer W., Ramanathan R.K., Goldstein D., Penenberg D.N. et al. Prognostic Factors of Survival in a Randomized Phase III Trial (MPACT) of Weekly NabPaclitaxel Plus Gemcitabine Versus Gemcitabine Alone in Patients With Metastatic Pancreatic Cancer. The Oncologist. 2015;20(2):143–150. doi:10.1634/theoncologist.2014-0394.; Giordano G., Milella M., Lo Re G., Di Marco M., Melisi D., Passardi A., Febbraro A., Iop A., Vaccaro V., Foltran L. et al. Nab-Paclitaxel (Nab-P) and Gemcitabine (G) First-Line Chemotherapy (CT) in Patients (Pts) with Metastatic Pancreatic Cancer (MPC) Who Relapsed after Adjuvant Treatment (ADJ T): A «REAL LIFE» Study. JCO. 2017;35(4):396–396. doi:10.1200/JCO.2017.35.4_suppl.396.; Scheithauer W., Ramanathan R.K., Moore M., Macarulla T., Goldstein D., Hammel P., Kunzmann V., Liu H., McGovern D., Romano A. et al. Dose Modification and Efficacy of Nab -Paclitaxel plus Gemcitabine vs . Gemcitabine for Patients with Metastatic Pancreatic Cancer: Phase III MPACT Trial. Journal of Gastrointestinal Oncology. 2016;7(3); https://www.med-sovet.pro/jour/article/view/5190

الاتاحة: https://www.med-sovet.pro/jour/article/view/5190
https://doi.org/10.21518/2079-701X-2019-19-74-82